Alphyn Biologics' AB-101 Atopic Dermatitis Treatment Shows Promise in Ongoing Phase 2a Trial

Alphyn Biologics Reports Positive Results from First Cohort of Phase 2a Trial of Atopic Dermatitis Treatment
The trial met all of its primary endpoints, highlighting AB-101a's potential to be an effective and safe treatment for AD.

Alphyn Biologics shared positive results from the first cohort of its Phase 2a clinical trial of AB-101a, a topical therapeutic for mild-to-moderate atopic dermatitis (AD). The trial met all of its primary endpoints, highlighting AB-101a's potential to be an effective and safe treatment for AD. 

The randomized, vehicle-controlled, double-blind trial evaluated the treatment protocol of AB-101a across multiple sites using standard scales for assessing AD. The trial, conducted in Australia, enrolled 41 AD patients and treatment was evaluated after four weeks. 

"As a physician who treated 15% of the patients in the clinical trial, I am encouraged by the results with AB-101a," said Stephen Shumack, OAM, FACD, clinical associate professor dermatology for the University of Sydney, and principal investigator at St George Dermatology & Skin Cancer Centre. "I look forward to future trials and gaining a better understanding of AB-101a's potential benefits for patients."

Related: Amytrx Therapeutics Raises $18M for Therapeutic Interventions of Atopic Dermatitis

Second Cohort of Phase 2a Clinical Trial

Alphyn plans to present the full results of this trial at a scientific conference and submit a paper for publication in a peer-reviewed journal. The enrollment is ongoing in the second cohort of the Phase 2a clinical trial. The second cohort will investigate the ability of AB-101a to treat the infected component of AD in patients who are suffering from bacterial infections including Staphylococcus aureus, or "Staph," and MRSA, the antibiotic-resistant Staph.

The company anticipates AB-101a will be effective in treating non-infected AD and infected AD. AB-101a is expected to provide AD patients and physicians a comprehensive, safe and convenient treatment option. 

AB-101a was created using Alphyn's proprietary AB-101 platform, which has multiple bioative compounds and, therefore, multiple mechanisms of action to address the problems of any target disease. The company was able to begin the AB-101a clinical trial program in Phase 2 due to the strong safety profile of its AB-101 platform. 

More in Skin Care